Search the Newsreel

Mirion Technologies (NYSE: MIR) posts Q2 2026 growth, keeps full-year guidance

Mirion Technologies reported strong second-quarter 2026 results, with revenue growing 19.7% to $266.8 million and Adjusted EBITDA increasing 27.5% to $65.3 million. The company reaffirmed its full-year 2026 guidance, projecting total revenue growth of 22.0%–24.0% and Adjusted EBITDA between $285 million and $300 million, …

TELO|Telomir Pharmaceuticals Inc|Price:1.210|Chg%:-0.040

Telomir Pharmaceuticals Inc. (TELO) is a preclinical-stage pharmaceutical company focused on developing Telomir-1, a novel small molecule designed to lengthen protective telomere caps to combat age-related conditions such as Progeria, Wilson's disease, and Alzheimer's. The company aims to commercialize Telomir-1, an orally dosed drug, …

Telomir Pharmaceuticals Inc (TELO) Income Statement

This article presents the quarterly and annual income statements for Telomir Pharmaceuticals Inc (TELO), detailing financial performance metrics such as total revenue, operating expenses, R&D expenses, operating profit, and net income. The data spans from FY2022Q1 to FY2026Q1, highlighting the company's consistent losses across …

The Scotts Miracle-Gro Company Announces Quarterly Dividend Payment

The Scotts Miracle-Gro Company (NYSE: SMG) has announced that its Board of Directors approved a cash dividend payment of $0.66 per share. The dividend is scheduled to be paid on September 4, 2026, to shareholders of record as of August 21, 2026. The company …

Regina Miracle International (Holdings) Limited Revenue Breakdown – HKEX:2199

Mirion Technologies Q2 EPS beats estimate despite revenue miss

Earnings Flash (MIR) Mirion Technologies, Inc. Reports Q2 Revenue $266.8M, vs. FactSet Est of $269.3M

Mirion Technologies (NYSE:MIR) Releases FY 2026 Earnings Guidance

Mirion Announces Second Quarter 2026 Financial Results

Revenues for the second quarter increased 19.7% to $266.8 million, compared to $222.9 millionin the same period in 2025. GAAP net income was $8.1 millionin the second quarter, a 4.7% decrease compared to GAAP net income of $8.5 millionin the same period in 2025; …

Telomir Pharmaceuticals (TELO) awards director 50,000 options at $1.34 exercise price

Telomir Pharmaceuticals (TELO) has granted director Edward Clouston MacPherson 50,000 non-qualified stock options at an exercise price of $1.34 per share. The options, which vested immediately, were issued on April 16, 2026, under the company's 2023 Omnibus Incentive Plan and expire on April 16, …

Is the Options Market Predicting a Spike in Mirion Technologies Stock?

Investors in Mirion Technologies, Inc. MIR need to pay close attention to the stock based on moves in the options market lately. That is because the Nov. 20, 2026 $2.5 Call had some of the highest implied volatility of all equity options today. What …

Telomir Pharmaceuticals Inc (TELO) Institutional Confidence

This article from TradingKey provides an overview of Telomir Pharmaceuticals Inc (TELO)'s institutional confidence, highlighting its current stock performance and market capitalization. It details the institutional shareholdings and recent shareholder activity, including changes in holdings by key investors such as Aminov (Erez) and BlackRock …

Earnings To Watch: Mirion (MIR) Reports Q2 Results Tomorrow

Earnings To Watch: Mirion (MIR) Reports Q2 Results Tomorrow Radiation safety company Mirion (NYSE:MIR) will be announcing earnings results this Tuesday afternoon. Here's what to expect. Mirion beat analysts' revenue expectations last quarter, reporting revenues of $257.6 million, up 27.5% year on year. It …

Mira Pharmaceuticals Inc (MIRA) Financial Health: Profitability & Balance Sheet Analysis

Mira Pharmaceuticals Inc (MIRA) currently holds a financial score of 7.04, ranking 155 out of 386 in the Biotechnology & Medical Research industry, indicating a robust financial status despite low operating efficiency. The report highlights various financial and operational metrics, such as Quality of …

Mirum Pharmaceuticals Inc (MIRM) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Mirum Pharmaceuticals Inc (MIRM), listing major individual and institutional holders and their respective proportions. It also presents institutional shareholding trends over several quarters and highlights related ETFs that hold MIRM. Key information includes top shareholders like Frazier …

Mirum Pharmaceuticals Inc (MIRM) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Mirum Pharmaceuticals Inc (MIRM) stock, focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years. The page displays current stock metrics such as market capitalization …

Telomir Pharmaceuticals Inc (TELO) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides a dividend and stock split report for Telomir Pharmaceuticals Inc (TELO), noting that the company has distributed $0.00 in dividends over the past five years. It indicates that there is no historical dividend data available for the company. The page also …

Mira Pharmaceuticals Inc (MIRA) Income Statement

This article provides the quarterly and annual income statements for Mira Pharmaceuticals Inc (MIRA), offering detailed financial data on total revenue, operating expenses, R&D expenses, operating profit, and net income. It includes historical data from FY2021Q1 to FY2026Q1, highlighting key financial metrics and year-over-year …

Mira Pharmaceuticals Inc (MIRA) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides an overview of Mira Pharmaceuticals Inc (MIRA) dividends and stock splits, noting that no dividend data is available and zero dividends have been distributed in the past five years. It also includes current stock information, showing MIRA trading at $0.882 with …

Mirum Pharmaceuticals, Inc. Revenue Breakdown – BIVA:MIRM

Mirum Pharmaceuticals, Inc. (MIRM) generated 9.40 billion MXN in total revenue last year, primarily from its Pharmaceutical segment. The United States was the largest contributor to its revenue, accounting for 7.24 billion MXN. This represents an increase from the previous year's revenue of 7.01 …

Telomir Pharmaceuticals Inc (TELO) Cash Flow Statement

This article provides the quarterly and annual cash flow statements for Telomir Pharmaceuticals Inc (TELO), detailing its operating, investing, and financing cash flows. It includes financial data from FY2022Q3 through FY2026Q1, along with explanations of key cash flow terms and how to interpret them …

Mirrabooka Investments (ASX:MIR): Why This LIC's Fully Franked Final Dividend Is Worth Watching

Telomir Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:TELO

This page provides financial information for Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), including an overview of its financials, statements, statistics, dividends, earnings, and segments. It also details the top segments and regional performance by source and country, with market data provided by ICE Data Services …

Emira Property Fund Ltd. Revenue Breakdown – JSE:EMI

MIRA Pharmaceuticals, Inc. Revenue Breakdown – LSX:A3EQWL

The article provides a financial overview of MIRA Pharmaceuticals, Inc. (A3EQWL) on the Lang & Schwarz Exchange, detailing available fundamental and statistical data such as overview, statements, statistics, dividends, earnings, and segments. It specifically highlights the company's revenue breakdown by source and country. The …

Mirae Asset Securities Shares Tumble Despite Record Profit Forecast… Is SpaceX Becoming a Liability?

Mirion Technologies, Inc. Revenue Breakdown – NYSE:MIR

Stifel reiterates Mirum Pharmaceuticals stock rating after rival trial fails

Stifel maintained its Buy rating and $136.00 price target for Mirum Pharmaceuticals (NASDAQ:MIRM) following the failure of a competitor's Phase 3 clinical trial in biliary atresia. The firm noted that Mirum's own EXPAND study, with data expected in Q4 2026, is de-risked and sees …

Scotts Miracle-Gro Company (The) Revenue Breakdown – NYSE:SMG

MIRM|Mirum Pharmaceuticals Inc|Price:113.030|Chg%:-1.330

Mirum Pharmaceuticals Inc. (MIRM) closed at $113.03, down 1.16%, with a market cap of $6.89B. The company, focused on rare disease treatments, is considered to have healthy fundamentals, high growth potential, and a fairly valued assessment, with a strong buy rating from analysts. Its …

Scotts Miracle Gro (SMG) Stock May Sit Below Fair Value On A 54% Five Year Slump

Scotts Miracle-Gro (SMG) stock has experienced a 54.4% decline over the past five years, despite a 13.6% gain year-to-date. A Discounted Cash Flow (DCF) model suggests the stock is currently undervalued by about 17.3%, trading at a discount to its intrinsic value of $81.68 …

MIRM Financials

Mirum Pharmaceuticals Inc. (MIRM) closed at $113.030 with a -1.16% change. The article provides a comprehensive financial overview of Mirum Pharmaceuticals Inc., detailing its income statement, balance sheet, and cash flow statement through Q1 2026 and historical data. It also highlights key financial indicators, …

MIRA|Mira Pharmaceuticals Inc|Price:0.882|Chg%:-0.046

Mira Pharmaceuticals Inc (MIRA) closed at $0.882, down 4.97% on July 24th, 2026. The company, a clinical-stage pharmaceutical firm, focuses on developing therapeutics for neurological, neuropsychiatric, and metabolic disorders, including Ketamir-2 and SKNY-1 in its pipeline. Despite strong fundamentals and high growth potential, the …

Telomir Pharmaceuticals Inc (TELO) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Telomir Pharmaceuticals Inc (TELO), which has a current financial score of 6.88 out of 10, ranking 131st out of 155 in the Pharmaceuticals industry. The analysis indicates robust financial status but low operating efficiency. Key financial metrics …

Almirall SA (STU:E2Z) Q2 2026 Earnings Call Highlights: Strong Growth in Dermatology and ...

This article first appeared on GuruFocus. Net Sales: EUR603 million, a 7.5% growth year-on-year. Ilumetri Sales: EUR125 million in the first half, marking a 10.5% year-on-year increase. Ebglyss Sales: Approximately EUR85 million in the first half, nearly doubling year-on-year. EBITDA: EUR151 million, representing 25% …

Almirall H1 2026 Results

Almirall delivers solid H1 2026 results growing Net Sales by 7.5% and EBITDA by 23.7%, driven by its strong European Dermatology business – reiterating guidance aligned with long-term growth trajectory Net Sales increased by 7.5% YoY to €602.7 MM, while EBITDA grew by 23.7% …